Preimplantation Genetic Testing Pgt Market Size, Share and Growth Analysis Report - Forecast Trends and Outlook 2026-2030

PGT encompasses several testing modalities, including PGT-A (aneuploidy screening), PGT-M (monogenic disease testing), and PGT-SR (structural rearrangement testing), each serving distinct clinical purposes in the IVF workflow. The market has shifted significantly toward next-generation sequencing platforms, which offer higher resolution and throughput compared to older array-based methods. Fertility clinics and specialized reproductive centers process the majority of IVF cycles globally, and PGT-A for euploid embryo selection has become a standard offering in many of these facilities, contributing to the market's sustained growth trajectory through the latter half of the decade.

• •The market is valued at approximately $852 million in 2024, with a 2026 estimate of $739 million, and is projected to reach between $1.1 billion and $1.4 billion by 2030 depending on methodology
• •PGT-A (aneuploidy screening) dominates clinical adoption, with leading fertility centers achieving implantation rates near 65% through euploid embryo selection
• •Next-generation sequencing platforms have largely supplanted array-based comparative genomic hybridization (aCGH) as the preferred technology among major testing providers

One of the most significant growth catalysts is the rising average maternal age at first birth across developed and emerging markets, as advanced maternal age correlates strongly with increased rates of embryonic aneuploidy and the corresponding demand for PGT-A screening. Declining costs associated with sequencing and automation are making PGT more accessible outside premium-tier clinics, while expanding insurance coverage and reimbursement frameworks in key markets are reducing out-of-pocket costs for patients. Additionally, growing awareness among fertility specialists and patients about the clinical benefits of preimplantation genetic screening, particularly in reducing miscarriage rates and improving IVF success rates, is fueling adoption across a broader patient population.

• •Rising average maternal age and increasing prevalence of genetic disorders among reproductive-age populations are accelerating demand for PGT services globally
• •Technological improvements in sequencing throughput and sample automation have substantially lowered per-test costs, expanding accessibility to mid-tier and regional fertility centers
• •Broadening insurance coverage for PGT in major healthcare systems is removing a significant financial barrier and driving higher utilization rates

By product and service type, the market includes reagent and kit consumables, instrument platforms, and outsourced laboratory testing services, with consumables representing the largest recurring revenue stream. By procedure type, PGT-A commands the dominant share due to its broader clinical application, while PGT-M and PGT-SR represent smaller but high-value specialized segments. Regionally, North America accounts for the largest share of global market revenue, supported by high IVF volumes, favorable reimbursement policies, and early adoption of advanced sequencing technologies. Europe represents the second-largest regional market, with Asia-Pacific emerging as the fastest-growing region driven by rising fertility treatment demand in China, India, and Southeast Asian economies, alongside improving access to assisted reproductive technology infrastructure.

• •Fertility centers constitute the largest end-use segment, processing approximately 70% of global IVF cycles that incorporate PGT services
• •North America leads in revenue contribution, while Asia-Pacific is the fastest-expanding region due to rising IVF adoption and increasing healthcare expenditure
• •The PGT-A segment accounts for the majority of testing volume, whereas PGT-M and PGT-SR serve smaller patient populations with higher per-test pricing

Who are the notable companies in the industry?

The competitive structure of the PGT market is characterized by moderate to high consolidation, with a limited number of large vertically integrated players controlling significant shares of global technology and service provision. These firms span the full value chain from instrument and reagent manufacturing to centralized reference laboratory testing services, creating barriers to entry through proprietary platform licensing, regulatory approvals, and established clinical relationships. Capacity is concentrated among a small number of vertically integrated providers, with most major players maintaining reference laboratory networks across North America, Europe, and select Asia-Pacific markets to serve fertility clinic clients on a turnaround basis.

• •The market exhibits moderate to high consolidation, with a small number of vertically integrated players dominating global capacity and technology platforms
• •Leading participants operate across the full value chain, from sequencing instrumentation and consumables to outsourced laboratory services, creating structural barriers for new entrants
• •Regional capacity is concentrated in North America and Europe, with reference laboratory networks serving as the primary channel through which most fertility clinics access PGT services

What are the recent trends and outlook?

The market is witnessing a growing trend toward comprehensive chromosome screening at the blastocyst stage, driven by evidence that such approaches yield higher pregnancy rates and lower miscarriage rates compared to earlier-stage biopsy methods. Advances in time-lapse imaging combined with non-invasive genetic screening techniques are emerging as potential disruptors, offering the possibility of genetic analysis without embryo biopsy, a development that could significantly reshape the competitive landscape. Over the forecast period, the convergence of artificial intelligence in embryo selection, expanded use of PGT for screening of adult-onset conditions, and continued geographic market expansion into Latin America, the Middle East, and South Asia are expected to sustain growth momentum and potentially accelerate market development beyond baseline CAGR projections.

• •Non-invasive preimplantation genetic testing (niPGT) via spent embryo culture media is an emerging approach that could reduce procedural risk and broaden market adoption
• •Artificial intelligence and machine learning integration with time-lapse embryo monitoring is increasingly complementing or potentially supplanting traditional morphologic assessment in some clinic workflows
• •Geographic expansion into Latin America, the Middle East, and South Asia represents an underpenetrated opportunity as IVF infrastructure continues to develop in these regions